Sample Size Calculation in Oncology Trials Quality of Reporting and Implications for Clinical Cancer Research
Carregando...
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2015
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
PRECIVALE, Maristela
SAAD, Everardo D.
Citação
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, v.38, n.6, p.570-574, 2015
Resumo
Objectives:Sample size calculation (SSC) is a pivotal step in clinical trial conception and design. Herein, we describe the frequency with which oncology phase III trials report the parameters required for SSC.Materials and Methods:We systematically searched for phase III trials published in 6 leading journals, which were accompanied by editorials from January 2008 to October 2011. Two blinded investigators extracted required and optional parameters for SSC according to the primary endpoint.Results:We retrieved 140 eligible phase III trials. The median target sample size was 596 subjects (50 to 40,000); in 66.4% of cases, the number of enrolled subjects was at least 90% of the target. The primary endpoint was a continuous variable in 5.7%, categorical in 30.0%, and a time-to-event variable in 64.3% of phase III trials. Although nearly 80% reported a target sample size, only 27.9% of the trials provided all the required parameters for proper SSC. The most commonly reported parameters for sample size computation were (93.6%) and (90.7%) errors. The parameters least reported were the expected outcomes in the control or experimental groups, each provided in only 57.9% of trials.Conclusions:The quality of SSC reporting in phase III cancer trials is poor. Such incomplete reporting may compromise future study designs, pooling of data, and interpretation of results. Lack of transparency in SSC reporting may also have ethical implications.
Palavras-chave
sample size calculation, randomized clinical trial, study design
Referências
- ALTMAN DG, 1980, BRIT MED J, V281, P1336
- Altman Douglas G, 2002, BMJ, V325, P491
- Schulz KF, 2005, LANCET, V365, P1348, DOI 10.1016/S0140-6736(05)61034-3
- Toulmonde M, 2011, J CLIN ONCOL, V29, P1204, DOI 10.1200/JCO.2010.30.9369
- Saad ED, 2012, ACTA ONCOL, V51, P890, DOI 10.3109/0284186X.2012.702924
- Ocana A, 2011, J CLIN ONCOL, V29, P1099, DOI 10.1200/JCO.2010.33.1462
- Simera I, 2012, MATURITAS, V72, P84, DOI 10.1016/j.maturitas.2012.02.012
- [Anonymous], AUTH CTR SUPPL APP
- Hui D, 2012, SUPPORT CARE CANCER, V20, P1779, DOI 10.1007/s00520-011-1275-9
- Fleming TR, 2011, CLIN TRIALS, V8, P432, DOI 10.1177/1740774511410994
- Bedard PL, 2007, J CLIN ONCOL, V25, P3482, DOI 10.1200/JCO.2007.11.3670
- You BO, 2012, J CLIN ONCOL, V30, P210, DOI 10.1200/JCO.2011.37.0890
- ROYALL RM, 1986, AM STAT, V40, P313, DOI 10.2307/2684616
- Latif LA, 2011, ARCH PHYS MED REHAB, V92, P306, DOI 10.1016/j.apmr.2010.10.003
- Bagai RK, 2006, J CLIN ONCOL S, V24
- Chan AW, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2299
- Charles P, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1732
- European Science Foundation, 2011, IMPL MED RES CLIN PR
- Gan HK, 2010, J CLIN ONCOL S, V28
- Halpern SD, 2002, JAMA-J AM MED ASSOC, V288, P358, DOI 10.1001/jama.288.3.358
- Meinert CL, 1986, CLIN TRIALS DESIGN C
- Schulz KF, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c332